We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $1.06B
1-Year Est. Return 52.03%
This Fund
S&P 500
This Quarter Est. Return
+22.03%
1 Year Est. Return
+52.03%
3 Year Est. Return
+131.18%
5 Year Est. Return
+187.67%
10 Year Est. Return
+1,140.82%
AUM
$1.06B
AUM Growth
+$249M
Cap. Flow
+$137M
Cap. Flow %
12.89%
Top 10 Hldgs %
25.08%
Holding
106
New
20
Increased
41
Reduced
34
Closed
7

Top Buys

Rank Stock Value
1
AZN icon
AstraZeneca
AZN
+$28.5M
2
MRK icon
Merck
MRK
+$25M
3
UNH icon
UnitedHealth
UNH
+$17.8M
4
JNJ icon
Johnson & Johnson
JNJ
+$16.9M
5
CNC icon
Centene
CNC
+$13M

Top Sells

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$14.1M
2
LLY icon
Eli Lilly
LLY
+$11.6M
3
VEEV icon
Veeva Systems
VEEV
+$11.2M
4
ADPT icon
Adaptive Biotechnologies
ADPT
+$9.99M
5
BSX icon
Boston Scientific
BSX
+$9.48M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
APGE
101
DELISTED
Apogee Therapeutics
APGE
– –
-75,000
Closed -$6.31M
CMPX icon
102
Compass Therapeutics
CMPX
$203M
– –
-115,113
Closed -$609K
ESPR
103
DELISTED
Esperion Therapeutics
ESPR
– –
-985,000
Closed -$2.7M
IMCR icon
104
Immunocore
IMCR
$1.58B
– –
-85,724
Closed -$2.58M
IQV icon
105
IQVIA
IQV
$44.5B
– –
-53,000
Closed -$9.04M
NUVL
106
DELISTED
Nuvalent
NUVL
– –
-81,200
Closed -$8.32M
1 2 3 4
5

Similar funds

JSC
J. Stern & Co London, United Kingdom $1.06B AUM 11.76% 1-Year Est. Return
PCI
Planning Center Inc Moline, Illinois $1.06B AUM 12.82% 1-Year Est. Return
SAM
Synergy Asset Management Vancouver, Washington $1.06B AUM 36.26% 1-Year Est. Return
PCM
Polaris Capital Management Boston, Massachusetts $1.06B AUM 40.82% 1-Year Est. Return
BDP
Brehaut David Pascal $1.06B AUM
GX
Greylock XIV Menlo Park, California $1.06B AUM
CIC
Cutler Investment Counsel Jacksonville, Oregon $1.06B AUM 20.29% 1-Year Est. Return
RCIM
Red Cedar Investment Management Grand Rapids, Michigan $1.06B AUM 30.61% 1-Year Est. Return

Rhenman & Partners Asset Management's Q2 2026 Portfolio in Review

As of Q2 2026, Rhenman & Partners Asset Management held 106 positions worth $1.06B, up 31% from $810M the previous quarter. Its ten largest holdings account for 25% of the portfolio.

Rhenman & Partners Asset Management deployed $137M of net new capital in Q2 2026, opening 20 new positions and adding to 41 existing holdings. Its largest new stake was AstraZeneca: 151,500 shares worth $28.5M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Regeneron Pharmaceuticals, an estimated $14.1M trimmed.

  • Rhenman & Partners Asset Management's largest Q2 2026 buy was AstraZeneca: 151,500 shares worth $28.5M.
  • Rhenman & Partners Asset Management added most to UnitedHealth in Q2 2026, an estimated $17.8M increase.
  • Rhenman & Partners Asset Management's biggest Q2 2026 reduction was Regeneron Pharmaceuticals, cutting an estimated $14.1M.
  • Rhenman & Partners Asset Management fully exited Adaptive Biotechnologies in Q2 2026, selling an estimated $9.99M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 25% of its $1.06B portfolio in Q2 2026.
  • Rhenman & Partners Asset Management opened 20 new positions and closed 7 in Q2 2026.
  • Rhenman & Partners Asset Management's portfolio value rose 31% quarter-over-quarter to $1.06B.

Based on Rhenman & Partners Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.